BioSpace News Archive

Sophia L. Thomas, DNP, APRN, FNP-BC, PPCNP, FNAP, FAANP, president of American Association of Nurse Practitioners issued the following statement concerning efforts underway by policymakers and the nation’s 290,000 licensed nurse practitioners to combat the Coronavirus Disease 2019

The Minnesota Dental Association and the Minnesota Oral Health Coalition will host the Oral Health Showcase, an inaugural exhibit of oral health programs and organizations at the Minnesota State Capitol on March 12, 2020, from 3:00 p.m. to 5:00 p.m.

CrowdCare Founder and Patient Advocate Jenny Ahlstrom Says Patient Access to Data is the Key to Curing Disease

In response to the growing number of confirmed COVID-19 cases across the U.S., LHC Group, Inc. has established an internal multi-disciplinary COVID-19 task force to organize resources and coordinate efforts as the company joins the nation’s healthcare industry in confronting the virus..

A national medical society on Sunday recognized a study from the JFK Johnson Stroke-HEART™ Trials as the best research published last year in the field’s most prestigious journal.

Gilead Sciences Inc. (Nasdaq: GILD) today announced data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, BIC/FTC/TAF) in virologically suppressed adults living with HIV who self-identified as Black or African American.

As coronavirus paralyzes the world with fear, bioscience enterprise The Gilla Company has developed and independently tested a product shown to be at least 99.9% effective in killing the deadly virus.

Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083

NDA for Ripretinib for the Treatment of Advanced GIST Accepted for Priority Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Approval and Launch - - INTRIGUE Pivotal Phase 3 Study of Ripretinib in Second-line GIST Expected to Complete Enrollment in the Second Half of 2020 - - Ended 2019 with Cash, Cash Equivalents and Marketable Securities of $579.6 Million - - Company to Host

Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2019. “We’re pleased to close out another year of compelling growth, product launches, productive capital raises, key hires and technology adoption, mark